Sep 29, 2026 · 6 min
Chip contract and AI deal lift stocks as FICO faces disruption
Navitas Soars; AstraZeneca Invests $2 Billion in Summit; FICO Drops
The episode connects four market moves to larger shifts in defense technology, cancer-drug financing, credit scoring, and artificial-intelligence competition.
- 1Navitas Semiconductor surged after winning a U.S. Army research program focused on high-voltage chips.
- 2AstraZeneca’s $2 billion investment lifted Summit Therapeutics while Fair Isaac shares fell on possible scoring changes.
- 3AMD’s planned $8.2 billion WorldLabs acquisition shows how aggressively companies are competing for AI expertise and models.
Don't miss
Fair Isaac’s decline reveals how a change in the credit-scoring grid could challenge the dominance of Classic FICO scores.
The brief
Bloomberg’s Stock Movers report tracks a market split between sharp gains and declines, using individual company moves to show where investors see strategic momentum or disruption.
Navitas Semiconductor rose after winning a U.S. government program to develop high-voltage chips, linking its stock move to defense research and advanced power technology.
Summit Therapeutics gained after AstraZeneca announced a $2 billion strategic investment tied to cancer-treatment research, making capital commitment the catalyst for the move.
Fair Isaac shares fell as regulators opened the door to broader VantageScore use, potentially reducing the importance of the company’s Classic FICO scores.
AMD’s planned $8.2 billion acquisition of WorldLabs would add researchers, models, and AI expertise, underscoring the sector’s intensifying competition for capability.
What was said on this episode
13 statements · 8 positive · 3 negative · 2 neutral
Navitas shares rose 13% in premarket trading.
“Navitas, NVTS, is up 13% in the premarket.”
Listen at 0:43
Navitas won a contract to develop a high-voltage next-generation chip.
“The semimaker won a U.S. government contract to develop a next-generation chip capable of handling high voltages.”
Listen at 0:46
Navitas chips could be used in high-power military electrical systems.
“these potentially could go into high-power electrical military systems”
Listen at 1:00
Higher-voltage systems would likely benefit data-center buildouts.
“higher voltage systems would probably be better, would probably benefit them as well”
Listen at 1:12
Any contract would be highly positive for Navitas.
“any deal seems to be a very positive thing for this company”
Listen at 1:28
Summit Therapeutics shares rose 19%.
“Summit Therapeutics, another big gainer, this one up 19% under ticker SMMT.”
Listen at 1:37
Summit’s drug is being used in multiple Phase 3 clinical trials.
“Summit's drug is currently utilized in multiple Phase 3 clinical trials”
Listen at 2:02
Summit’s drug lacks approval in its licensed territories.
“it hasn't been approved in Summit's licensed territories yet”
Listen at 2:06
Fair Isaac shares fell 13%.
“the share is down 13% and it trades under ticker FICO”
Listen at 2:28
VantageScore typically produces higher credit scores than Classic FICO.
“Since VantageScore typically has higher credit scores”
Listen at 2:49
The scoring-grid change could boost VantageScore as borrowers seek lower borrowing costs.
“this is seen as a potential boost for the former as borrowers move towards the credit rating that gives them lower borrowing costs.”
Listen at 3:00
Fair Isaac could lose clients because of the scoring-grid change.
“So potential loss of clients for Fair Isaac, that stock under pressure.”
Listen at 3:06
The WorldLabs acquisition adds researchers, models, and AI-development insights to AMD.
“The purchase adds a team of researchers and their models, along with their insights into how the field is developing.”
Listen at 3:36
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
FICO
FHA
Bloomberg: Business News DailyListen to the full episode and explore every guest, topic, and moment on PodLume.